ERN-EYE Webinar – CRISPR and RNA / ASO therapies

ERN-EYE Webinar – CRISPR and RNA / ASO therapies

Date and time

Friday 16 January, 1.00 pm CEST.

Programme

Chair: Prof. Camiel Boon, Amsterdam University Medical Center, Amsterdam, The Netherlands.

1. The Therapeutic Promise of the 21st Century: Power and Limits of Gene Editing, Dr. Pietro De Angeli, University Hospitals Tübingen, Germany.
2. ECMP – Crispr clinic, Prof. Dr. Mieke van Halest, Department of Clinical Genetics, Amsterdam UMC.
   
3. Splicing modulation therapy for inherited retinal diseases: towards personalized intervention, Prof. Dr. Rob Collin, Radboud University, The Netherlands

Registration

Prof. Dr. Mieke van Haelst

Prof. Dr. Mieke van Haelst is head of clinical genetics at Amsterdam UMC. As director of the Emma Centre for Personalised Medicine, she works on accelerated diagnostics, therapy development and treatment of rare diseases.

Her scientific research focuses on identifying and understanding the contribution of (epi)genetic factors to hereditary disorders. Outside Amsterdam UMC, Mieke conducts scientific and educational activities in India and the Dutch Caribbean, where she strives to provide equal care for diverse populations during her annual clinical consultations.

Prof. Dr. Rob Collin

Prof. Dr. Rob Collin is a professor of molecular genetics at Radboud University Medical Centre in Nijmegen, the Netherlands. He leads the Collin-Garanto Lab, where he works on the development of innovative molecular therapies for inherited retinal diseases.

His scientific research focuses on understanding the genetic mechanisms underlying retinal disorders and translating this knowledge into novel therapeutic strategies, including gene- and splicing-based therapies. Through his work, Prof. Collin aims to accelerate the development of effective treatments for patients with genetic visual impairments.

Chair: Prof. Camiel Boon, Amsterdam University Medical Center, Amsterdam, The Netherlands.

Camiel Boon, MD, PhD, FEBO, is a Consultant Ophthalmologist at Amsterdam University Medical Center, and Leiden University Medical Center (the Netherlands). At the age of 36, he was appointed as an Professor of Ophthalmology, with a special appointment for Clinical Ophthalmogenetics, at the University of Amsterdam.

At the age of 39, he was appointed as an Professor of Ophthalmology at Leiden University.

Clinically, Prof. Boon is specialized in medical retina, vitreoretinal surgery, and hereditary retinal diseases. He received his training as ophthalmologist at Radboud University Medical Center (Nijmegen, the Netherlands), however he also received his PhD on hereditary retinal diseases with the highest distinction (cum laude), as well as achieved several awards.

He subsequently did a medical retina and vitreoretinal surgery fellowship at the Oxford Eye Hospital (Oxford, United Kingdom), an observation training at the Vitreous Macula Retina Consultants of New York (VRMNY), followed by a vitreoretinal surgery fellowship at The Rotterdam Eye Hospital (Rotterdam, the Netherlands).

Scientifically, Prof. Boon’s research group focuses on clinical and genetic characteristics of hereditary retinal diseases, and the development of innovative treatments such as gene therapy. In addition, his research group is renowned for ground-breaking research on central serous chorioretinopathy, and age-related macular degeneration. He has extensive experience as initiator and principal investigator in a range of pioneering clinical trials, and has several clinical phenotypes for the first time. Prof. Boon has published more than 280 peer-reviewed articles on the mentioned topics, and is edited/co-authorised on chapters in a range of atlases.